Technical Analysis for VRPX - Virpax Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 14 hours ago |
| 1.5x Volume Pace | about 14 hours ago |
| 3x Volume Pace | about 14 hours ago |
| 10x Volume Pace | about 14 hours ago |
| Down 5% | about 14 hours ago |
Get a Trading Assistant
- Earnings date: 05/14/2024
Virpax Pharmaceuticals, Inc. Description
Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Sciences Drugs Pain Euphoriants Opioids Influenza Pain Management Drug Delivery Analgesics Morphinans Post Traumatic Stress Disorder Drug Delivery Systems Heroin Bupivacaine Morphine Nasal Administration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.774 |
| 52 Week Low | 0.6811 |
| Average Volume | 83,677 |
| 200-Day Moving Average | 5.29 |
| 50-Day Moving Average | 3.45 |
| 20-Day Moving Average | 2.69 |
| 10-Day Moving Average | 2.25 |
| Average True Range | 0.49 |
| RSI (14) | 25.93 |
| ADX | 21.22 |
| +DI | 18.44 |
| -DI | 42.00 |
| Chandelier Exit (Long, 3 ATRs) | 2.58 |
| Chandelier Exit (Short, 3 ATRs) | 2.14 |
| Upper Bollinger Bands | 4.02 |
| Lower Bollinger Band | 1.36 |
| Percent B (%b) | -0.22 |
| BandWidth | 98.76 |
| MACD Line | -0.43 |
| MACD Signal Line | -0.35 |
| MACD Histogram | -0.0809 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.14 | ||||
| Resistance 3 (R3) | 1.15 | 1.03 | 1.08 | ||
| Resistance 2 (R2) | 1.03 | 0.94 | 1.03 | 1.06 | |
| Resistance 1 (R1) | 0.91 | 0.89 | 0.85 | 0.90 | 1.04 |
| Pivot Point | 0.79 | 0.79 | 0.77 | 0.79 | 0.79 |
| Support 1 (S1) | 0.67 | 0.70 | 0.61 | 0.66 | 0.52 |
| Support 2 (S2) | 0.55 | 0.65 | 0.55 | 0.50 | |
| Support 3 (S3) | 0.43 | 0.55 | 0.48 | ||
| Support 4 (S4) | 0.42 |
